Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 16   

Articles published

VRUS 0.0000
price chart
Ralph Nader: The myths of corporate capitalism
Apple Inc. is spending $130 billion of its retained profits on a capital return program, $90 billion of which it will use to repurchase its own stock through 2015.
Costly hepatitis C cure is dilemma for doctors
The debate around Sovaldi's cost pits patients' interests against the need to reward pharmaceutical innovation. Gilead, which got the medicine in 2011 with the $11 billion acquisition of Pharmasset Inc., says the pricing is appropriate considering the ...
Lucrative Drug Niche Sparks Legal Scramble  Wall Street Journal
Related articles »  
Gilead wins FDA approval of first cancer drug
The company has made several acquisitions over the past decade to expand into hepatitis, including the controversial $1,000-a-pill hepatitis C drug Sovaldi that it received in its $11 billion January 2011 acquisition of Pharmasset Inc. Gilead, led by ...
Related articles »  
Gilead Earnings Preview: Non-Sovaldi Sales Bogey Of $2.94B May Be ...
Gilead Sciences, Inc. (NASDAQ:GILD) reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.
Gilead Sciences, Inc. (GILD), Apple Inc. (AAPL) and Twitter Inc (TWTR): Cramer ...
Gilead Sciences, Inc. (NASDAQ:GILD) bought Pharmasset, Inc. for $11 billion three years ago and with 89% premium which looked overpaid because the company had handful of assets with no real sales.
Latest Developments: Gilead Sciences Inc. (NASDAQ:GILD), StemCells Inc ...  Market News Call
Related articles »  
Senators want answers about Sovaldi's price tag
The senators also are seeking detailed information about the company's November 2011 purchase of Pharmasset Inc., the original developer of Sovaldi.
Wyden battles drug maker over hep C drug price  Portland Business Journal (blog)
Senators Demand Pricing Details On $1000-Per-Pill Sovaldi  Law360 (subscription)
Related articles »  
Federal Lawmakers Ask Gilead to Explain High Cost of Hepatitis C Drug
... Gilead acquired Sovaldi with the $11.2 billion purchase of Pharmasset Inc., the original developer, which expected to profitably sell the drug at a much lower price of $36,000, states the letter citing documents from the Securities and Exchange ...
LIMITED-TIME OFFER SUBSCRIBE NOW
Pharmasset Inc. spent $62 million developing the drug, according to the senators' letter. Sales of the drug generated as much as $3.3 billion in the first quarter of this year.
Related articles »  
Senators Seek Details on Gilead's Solvaldi Pricing
The original developer of Sovaldi� Pharmasset Inc.� which Gilead acquired in 2012 for $11.2 billion, expected to profitably sell the drug in the United States for $36,000, according to Securities and Exchange Commission (SEC) documents.
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips ...
Meanwhile, Gilead Sciences Inc.'s ( GILD ) hepatitis C drug made it to the news yet again thanks to its price tag. Apart from this ... The U.S. Senate has asked Gilead to provide it with information on Sovaldi as well as the Pharmasset acquisition ...
Related articles »